title: A report from CPhI Worldwide 2013, Fifth Annual Pre-Connect Conference (October 22-24, 2013 - Frankfurt, Germany).
abstract: A day before the start of the 2013 Conference on Pharmaceutical Ingredients (CPhI) Worldwide, the world's leading pharmaceutical networking event, a number of attendees gathered for the Fifth Annual Pre-Connect Conference to discuss trends in business development, manufacturing and regulatory arenas. Of the six modules presented at the meeting, one was dedicated to the sourcing environment in emerging markets, with special attention paid to developments in India and China. Other modules evaluated the current trends in the creation of generics and supergenerics in emerging markets. Additionally, there were updates on issues surrounding the regulatory and development hurdles that biosimilars and biobetters are facing today. Common themes for both discussions include appropriate pricing and erosion demographics for generics and biosimilars, licensing scenarios, commercialization strategies, and how to stay competitive and find novel innovations within new delivery systems, improved formulations and modifications to create better quality active pharmaceutical ingredients.
authors.affiliation: Thomson Reuters, Portland, Maine, USA. kate.kuhrt@thomsonreuters.com.
authors.forename: K
authors.initials: K
authors.lastname: Kuhrt
authors.forename: J
authors.initials: J
authors.lastname: Gilpatrick
mesh_terms: D059451:Biosimilar Pharmaceuticals; D002681:China; D016503:Drug Delivery Systems; D015195:Drug Design; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence / Q000458:organization & administration*; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D016568:Drugs, Generic / Q000191:economics / Q000600:supply & distribution; D006801:Humans; D007194:India; D004364:Pharmaceutical Preparations / Q000600:supply & distribution
chemical_list: D059451:Biosimilar Pharmaceuticals; D016568:Drugs, Generic; D004364:Pharmaceutical Preparations
keywords: Biosimilars and biobetters; Emerging markets; Regulatory compliance; Supergenerics